

MOL # 19299

Discovery of naturally occurring splice variants of the rat histamine H₃ receptor that act as dominant negatives*

Remko A. Bakker, Adrian Flores Lozada, André van Marle, Fiona C. Shenton, Guillaume Drutel, Kaj Karlstedt, Marcel Hoffmann, Minnamaija Lintunen, Yumiko Yamamoto, Richard M. van Rijn, Paul L. Chazot, Pertti Panula, and Rob Leurs.

The Leiden/Amsterdam Center for Drug Research, Department of Medicinal Chemistry, Vrije Universiteit Amsterdam, De Boelelaan 1083, 1081HV Amsterdam, The Netherlands (*RAB, AvM, GD, MH, RMvR, RL*)[§].

The Department of Biology, Åbo Akademi University, Biocity, Artillerigatan 6A, FIN-20520 Turku, Finland (*AFL, KK, ML, YY, PP*).

The Neuroscience Center, and Institute of Biomedicine/Anatomy, University of Helsinki, POB 63, FIN-00014 Helsinki, Finland (*PP*).

The School of Biological and Biomedical Sciences, University of Durham, South Road, DH1 3LE Durham, UK (*FCS, PLC*).

MOL # 19299

RUNNING TITLE PAGE

a) Running title: Discovery of dominant negative rat histamine H₃ isoforms.

b) Address correspondence to:

Prof. Dr. R. Leurs

The Leiden/Amsterdam Center for Drug Research, Department of Medicinal Chemistry, Vrije Universiteit Amsterdam, De Boelelaan 1083, 1081HV Amsterdam, The Netherlands. Tel. ++31 20 5987579; Fax. ++31 20 5987610; E-mail: r.leurs@few.vu.nl

c) Number of:

Text pages:	42
Tables:	0
Figures:	8
References:	47
Words in the <i>Abstract</i> :	235
Words in the <i>Introduction</i> :	561
Words in the <i>Discussion</i> :	1720

d) List of Non-standard abbreviations: GPCR, G-protein coupled receptor; seven-transmembrane-domain, 7TM; 7TM-rH₃R isoforms, the rH_{3A}, rH_{3B}, and rH_{3C} receptors; 6TM-rH₃R isoforms, the the rH_{3D}, rH_{3E}, and rH_{3F} isoforms; Pertussis Toxin, PTX; PTZ, pentylenetetrazole; ¹²⁵I-APT, [¹²⁵I]aminopotentidine; ¹²⁵IIPP, [¹²⁵I]iodophenpropit; ELISA, Enzyme-linked Immunosorbent Assay.

MOL # 19299

ABSTRACT

We previously described the cDNA cloning of three functional rat histamine H₃ receptor (rH₃R) isoforms as well as the differential brain expression patterns of their corresponding mRNAs and signalling properties of the resulting rH_{3A}, rH_{3B}, and rH_{3C} receptor isoforms (Drutel *et al.* (2001) *Mol Pharmacol.* 59:1-8). Herein we describe the cDNA cloning, mRNA localisation in the rat CNS and a pharmacological characterisation of three additional rH₃R splice variants (rH_{3D-F}) that differ from the previously published isoforms in that they result from an additional alternative-splicing event. These new H₃R isoforms lack the seventh transmembrane (TM) helix and contain an alternative, putatively extracellular, C-terminus (6TM-rH₃ isoforms). After heterologous expression in COS-7 cells, radioligand binding or functional responses upon the application of various H₃R ligands could not be detected for the 6TM-rH₃ isoforms. In contrast to the rH_{3A} receptor (rH_{3AR}), detection of the rH_{3D} isoform using HA-antibodies revealed that the rH_{3D} isoform remains mainly intracellular. The expression of the rH_{3D-F} splice variants, however, modulates the cell surface expression-levels and subsequent functional responses of the 7TM H₃R isoforms. Co-expression of the rH_{3AR} and the rH_{3D} isoforms resulted in the intracellular retention of the rH_{3AR} and reduced rH_{3AR} functionality. Finally, we show that in rat brain the H₃R mRNA expression levels are modulated upon treatment with the convulsant pentylenetetrazole, suggesting that the herein described rH₃R isoforms thus represent a novel physiological mechanism for controlling the activity of the histaminergic system.

MOL # 19299

INTRODUCTION

Histamine receptors are members of the superfamily of seven-transmembrane-domain (7TM) G-protein coupled receptors (GPCRs). The H₃R was pharmacologically identified in 1983 and holds great promise as a target for the development of therapeutics for numerous disorders, including obesity, epilepsy and cognitive diseases such as attention deficit hyperactivity disorder (ADHD) and Alzheimer's disease (see Bakker, 2004; Leurs et al., 2005 for reviews). The cloning of the histamine H₃ receptor (H₃R) cDNA allowed for the subsequent cloning of related sequences, including a variety of H₃R isoforms from different species (see Bakker, 2004; Leurs et al., 2005 for reviews).

Alternative splicing of pre-mRNA represents a widespread mechanism for increasing the variability of eukariotic gene expression by generating structurally distinct isoforms from a single gene. Alterations in the expression of GPCR isoforms could be associated with disease (Schmauss et al., 1993). Although α_1 -AR adrenoceptors and dopamine receptors are prime examples of alternatively spliced GPCRs (Cogé et al., 1999; Hawrylyshyn et al., 2004; Kilpatrick et al., 1999), more and more GPCR splice variants are identified for other members of the GPCR superfamily. A variety of H₃R isoforms from several species have been reported (see Bakker, 2004; Leurs et al., 2005 for reviews). In addition to the 445 amino acids containing rH_{3A}R two presumably non-functional truncated isoforms (reported as rH_{3T} or rH_{3(nf1)} and rH_{3(nf2)}) (Drutel et al., 2001; Morisset et al., 2001), and three functional rH₃R isoforms have been detected: rH_{3B}, rH_{3C}, and the rH₃₍₄₁₀₎ receptor, generated by deletions in the third intracellular loop of the rH₃R of 32, 48, and 35 amino acids, respectively. Since several H₃R isoforms have been shown to possess specific pharmacological characteristics in terms of ligand-binding and

MOL # 19299

initiation of signal-transductions events (Drutel et al., 2001), the H₃R mRNA splicing can significantly affect cellular responses to histamine. A detailed understanding of the spectrum of H₃R splice variants in different species is of importance not only for the understanding of histaminergic system, but also for future drug development efforts.

In the present study we describe the identification of three additional 6TM-rH₃ isoforms following an RT-PCR approach using rat brain cDNA. While the mRNA for these 6TM-rH₃ isoforms is detected in the rat brain, in attempting their characterisation, we failed to detect radioligand binding using H₃R specific radioligands as well as functional effects upon heterologous expression in COS-7 cells. Co-expression of 7TM-rH₃Rs with the 6TM-rH₃ isoforms, however, revealed that the 6TM-rH₃ isoforms inhibit the cell surface trafficking and subsequent functional activity of the 7TM-rH₃Rs. The regulation of the expression of the 6TM-rH₃ isoforms may therefore represent a novel mechanism for the regulation of H₃R functionality. To study possible *in vivo* functional relationships between 7TM-rH₃R and 6TM-rH₃ isoforms relative expression levels were analyzed in a model of generalized tonic-clonic seizures induced by pentylenetetrazole (PTZ). Data from a study on kainic acid-induced status epilepticus indicates that systemic kainic acid induces a direct or indirect selective increase in H₃R isoforms with a full third intracellular loop in areas which suffer rapid neuronal damage (Lintunen et al., 2005). Currently, no data is available whether 7TM-rH₃R and 6TM-rH₃ isoforms are similarly regulated under pathophysiological conditions in the rat brain. The PTZ seizure model used in this study allows us to determine if an H₃R isoform specific response occurs in a pathological setting. Our findings therefore uncover a new mechanism that may control the regulation of H₃R activity in the brain.

MOL # 19299

MATERIALS AND METHODS

Materials. Imnepip, clobenpropit, and thioperamide were synthesised at the department of Medicinal Chemistry at the Vrije Univeriteit Amsterdam. Gifts of pcDEF₃ (Dr. J. Langer), pTLN21CRE-Luc (Dr. W. Born) and of the cDNAs encoding the PTX insensitive mutant rat G $\alpha_{i/o}$ proteins G α_{i1} C³⁵¹I, G α_{i2} C³⁵²I, G α_{i3} C³⁵¹I, and G α_o C³⁵¹I (Dr. G. Milligan, University of Glasgow, UK), the cDNA encoding the FLAG-tagged rH_{3A}R (Dr. F. Cogé, Institut de Recherches Servier), the cDNA encoding the human histamine H₁ receptor (Dr. H. Fukui, University of Tokushima, Tokushima, Japan), the cDNA encoding the KSHV-GPCR ORF74 (Dr. T. Schwartz, University of Copenhagen), mianserin hydrochloride (Organon NV, The Netherlands), and the HA-antibody and Rhodamine labelled secondary antibody (Dr. J. van Minnen, Vrije Universiteit Amsterdam, The Netherlands), are greatly acknowledged. All other materials were from commercial suppliers.

Constructs. The reverse transcription and PCR amplification for cloning of the rH_{3D-F} (6TM-rH₃) isoform cDNAs were performed as described (Drutel et al., 2001). The full-length cDNAs were isolated with primers overlapping the rat H₃R cDNA sequence. The forward sequence included a Kozak sequence (underlined) (5'-CCG CCA CCA TGG AGC GCG CGC CGC CCG ACG GGC TG-3'). The reverse sequence was based on cDNA for rat orphan GPCR (Genbank accession number AB015646) (5'-CTC TAC CCC ATA ACC ACC CAC C-3'). The use of these primers resulted in the amplification of at least 3 different products. After cloning in pCRII-TOPO the cDNAs were sequenced on both DNA strands and subcloned in pcDNA₃. The sequence of the identified rH_{3F} isoform is identical to one of the sequences found in the GenBank[®] database (accession number AB015646, GI: 6681587), the sequences of the rH_{3D} and rH_{3E} isoforms have

MOL # 19299

been deposited in the GenBank[®] database (accession number DQ112342 and DQ112343, respectively). The hydrophobic profile of the H_{3D-F} isoforms was analysed using the TMHMM Server at the Center for Biological Sequence Analysis, Technical University of Denmark, DTU (<http://www.cbs.dtu.dk/services/TMHMM/>).

Construction of rH_{3R}-G_α protein fusion constructs. Fusion proteins between the rat H_{3R} and PTX insensitive mutant rat G_α-proteins of the G_{i/o} class were created by PCR using Turbo Pfu to remove the translation initiation codon from the G_α-protein cDNA sequence and the stop codon from the rH_{3A}R cDNA sequence.

HA-tagging of the rH_{3R} isoforms. N-terminal hemagglutinin (HA)-tagged expression constructs of the rH_{3A}R and rH_{3D} isoform were generated by PCR (5'-GCC ACC ATG GGC TAC CCA TAC GAC GTC CCA GAC TAC GCC GCG GAG CGC GCG CCG C-3') and cloned into pcDNA 3.1 (Invitrogen, Leek). Construct integrity was verified by sequence analysis.

Animals. The study was conducted in accordance with the European Convention (1986) guidelines and approved by the local committee for Animal Experiments and the Provincial State Office of Western Finland and the Animal Ethics Committee of Abo Akademi University. Male Sprague-Dawley rats (260-280 g) were given PTZ (50 mg/kg, i.p.). Animals were stunned with CO₂ and killed by decapitation 6h (PTZ, n = 3), 24h (PTZ, n = 3), and 48h (PTZ, n = 3; saline control, n = 3) post-injection.

In-situ hybridization histochemistry. Probes were labeled with deoxyadenosine 5'-triphosphate, [α -³³P] (New England Nuclear, Boston, USA) at their 3' ends using terminal deoxynucleotide transferase (Promega, Madison, WI), and subsequent *in-situ* hybridization histochemistry was

MOL # 19299

performed essentially as described previously (Drutel et al., 2001). The following oligo-probe sequence was used for detecting H_{3DEF} isoform mRNAs: 5'-AAG TTT CCC GAG GCG CTC GAC ACA GTA ATC GGG GAT GCA GCG GCC-3'.

Image analysis and data interpretation. Autoradiographic films were quantified by digitizing the film images using the MCID 5+ image analysis system (Imaging Research, St. Catherines, Ontario, Canada) and by measuring gray scale pixel values. The relative optic density was converted to integrated optic density (IOD) based on a curve derived from ¹⁴C standards exposed to films. Gray scale values were determined by using a total of four sections for each animal.

Cell culture and transfection. COS-7 African green monkey kidney cells were maintained and transfected as previously described (Bakker et al., 2004a; Drutel et al., 2001). HEK 293 cells were cultured under similar conditions and transfected with cDNA encoding the rH_{3AR} using the LipofectaminePlus method according to the manufacturer's protocols.

Reporter-gene assay. H_{3R} isoform-mediated modulation of cAMP mediated gene transcription activity was measured using the luciferase reporter-gene plasmid pTLNC121-3 (2.5 μg/1·10⁶ cells) containing 21 cAMP-responsive elements. Luminescence was assayed 48hr after incubation of transfected cells with ligands as described previously (Bakker et al., 2004b).

[³⁵S]GTPγS binding assays. Transfected COS-7 cells were resuspended in 4°C binding buffer (20mM HEPES, 3μM GDP, 10mM MgCl₂, 150mM NaOH, pH 7.4). For measurement of agonist-stimulated GTPγS binding, 6μg of the crude cell extract was incubated in binding buffer with

MOL # 19299

ligands for 15 min at 30°C after which 0.1–0.2 nM [³⁵S]GTPγS (Perkin Elmer Life Sciences, 1250 Ci/mmol) was added to make a final total volume of 100μL. Bound radioactivity was separated by filtration after 15 min through Whatman GF/C filters on a Brandel cell harvester using 4°C wash buffer (20mM HEPES, 5mM MgCl₂, pH 7.4). Radioactivity retained on the filters was measured by liquid scintillation counting.

Receptor binding studies. Radioligand binding studies for the H₁R, H₂R, and H₃R using [³H]mepyramine, [¹²⁵I]aminopotentidine (¹²⁵I-APT), and [*N*^α-methyl-³H]histamine, respectively, were performed as described previously (Bakker et al., 2004b). The H₃R radioligand binding studies using [¹²⁵I]iodophenpropit (¹²⁵IPP) were carried out under the same experimental conditions as for [*N*^α-methyl-³H]histamine. CXCL8 was labeled with ¹²⁵I using the Iodogen method (Pierce, Rockford, Ill.) and subsequently used in ORF74 radioligand binding studies as described previously (Smit et al., 2002).

Detection of tagged rH₃Rs. In the enzyme-linked immunosorbent assays (ELISA), a mouse anti-hemagglutinin (anti-HA) monoclonal primary antibody was used as primary antibody, and a goat anti-mouse–horseradish peroxidase conjugate as secondary antibody for the detection of tagged rH₃Rs in transfected cells. The 3,3',5,5'-tetramethylbenzidine liquid substrate system for ELISA was used as substrate and the optical density was measured at 450 nm using a Victor² Wallac multilabel counter (PerkinElmer, Boston, USA). The same primary antibody was used for immunocytochemistry in conjunction with a secondary rhodamine labelled Goat-anti-mouse antibody. Permeabilization of cells was achieved by an optional incubation of the cells for 5 min with 0.5% NP-40 in TBS prior to antibody application. For imaging, coverslips were mounted in

MOL # 19299

90% glycerol containing 0.02 M Tris-HCl (pH 8.0), 0.002% NaN₃, and 2% DABCO [1,4-diazabicyclo-(2,2,2)-octane; Merck, Darmstadt, Germany].

Time-resolved FRET. The *time-resolved* fluorescence resonance energy transfer (*tr*-FRET) experiments were conducted essentially as described previously (Bakker et al., 2004a). Energy transfer was measured by exciting the Eu³⁺ at 320 nm and monitoring the allophycocyanin emission for 1000 μs at 665 nm using a Novostar (BMG Labtechnologies) configured for time-resolved fluorescence after a 50 μs delay.

Cross-linking and immunoblotting of rH_{3A} receptors. Cells were harvested by centrifugation and the resulting pellet was resuspended in 150μl cross-linking buffer (150mM NaCl, 100mM Na-HEPES, 5mM EDTA pH7.5, 5mM DTT) to give a final protein concentration of approx. 0.5 mg/ml. The samples were incubated at room temperature with continual mixing for 12 minutes with either 0.12 or 0.25mM of the cell permeable cross-linker BS3 (bis(sulfosuccinimidyl)suberate), after which the cross-linking mixture was removed by centrifugation and the resultant pellet was used for immunoblotting as previously described (Chazot et al., 2001). Immunoblots were probed either with anti-H_{3C} 188-197Cys antibody (Shenton et al., 2005) at a 0.2 μg/ml, or with an anti-H₃ 329-358 antibody used at a final protein concentration of 1.5μg/ml (Chazot et al., 2001).

Analytical methods. All data shown are expressed as mean ± S.E.M. Data from radioligand binding assays and functional assays data were evaluated by a non-linear, least squares curve-fitting procedure using Graphpad Prism[®] (GraphPad Software, Inc., San Diego, CA).

MOL # 19299

RESULTS

Cloning of cDNAs encoding additional rat H₃R isoforms.

The existence of additional H₃R isoforms was investigated by RT-PCR analysis of rat whole-brain total RNA using specific primers 1 and 2 (see *Materials and Methods*), and revealed the existence of three previously uncharacterised full-length cDNAs with putative corresponding proteins of 497 (rH_{3D}), 465 (rH_{3E}), and 449 (rH_{3F}) amino acids. The amino acid sequence of the rH_{3F} isoform corresponds to one of the sequences found in the GenBank[®] database (accession number AB015646, GI: 6681587). These three new rH₃ isoforms correspond in a large part to the sequences of rat histamine H₃R isoforms A, B and C (rH_{3A}R, rH_{3B}R, and rH_{3C}R, respectively) and exhibit exactly the same differences in length for the third intracellular loop (IL3) (Figure 1A). This insertion in IL3 in the rH_{3D}, rH_{3E}, and rH_{3F} isoforms appears to be created by a retention/deletion system already described for the third intracellular loop (Cogé et al., 2001; Drutel et al., 2001; Morisset et al., 2001). However, the rH_{3D}, rH_{3E}, and rH_{3F} isoforms differ from the rH_{3A}R, rH_{3B}R, and rH_{3C}R in their C-terminal region, in which the last C-terminal 53 amino acids, which corresponding to the seventh transmembrane-domain and carboxy-terminus of the rH_{3A}R, rH_{3B}R, and rH_{3C}R proteins, are replaced by a sequence of 105 amino acids that do not share any homology with the last 53 C-terminal amino acids of the rH_{3A}R, rH_{3B}R, and rH_{3C}R. Sequence analysis of the rH_{3R} gene indicates that the alternative C-terminal domain that is found in the rH_{3D-F} isoforms is due to a change in the open reading frame upon alternative splicing using previously unidentified exon/intron junctions present within the rH_{3R} gene (see Figure 1B). Analysis of the hydrophobic profile of the rH_{3D}, rH_{3E}, and rH_{3F} isoforms does not reveal a clear putative seven transmembrane domain (Figures 2A and 2B).

MOL # 19299

Consequently, the rH_{3D}, rH_{3E}, and rH_{3F} isoforms are predicted to possess only six transmembrane domains (6TM-rH₃ isoforms) and an extracellular C-terminal domain (Figures 2C and 2D).

Heterologous expression of epitope-tagged rH₃R isoforms.

Previously we have successfully characterised the rH_{3A}R, rH_{3B}R, and rH_{3C}R using COS-7 cells heterologously expressing these receptors (Drutel et al., 2001). We therefore used the same approach in this study to characterise the herein described three additional 6TM-rH₃ isoforms. To evaluate the cell surface expression of the 6TM-rH₃ isoforms, we generated the cDNAs coding for the N-terminally HA-tagged rH_{3A}R (HA-rH_{3A}R) and the N-terminally HA-tagged rH_{3D} (HA-rH_{3D}) isoform by PCR. Whereas we detect clear immunological evidence for the cell surface expression of the HA-rH_{3A}R using an ELISA assay utilizing anti HA-antibodies on intact cells, we can hardly detect the HA-rH_{3D} isoforms on the cell surface on intact cells (Figure 2E). We observe, however, a clear immunofluorescent signal upon permeabilisation of cells expressing the HA-rH_{3D} isoform (Figure 2E), indicating successful synthesis of the HA-tagged rH_{3D} isoform protein and retention of the HA-tagged rH_{3D} isoform inside the cell. There is an apparent difference in detection of the HA-rH_{3D} isoform versus the HA-rH_{3A}R, which might indicate differences in e.g. the rate of synthesis, the inherent stability, or the rate of degradation of the H₃ isoforms, we have not pursued this issue further. To evaluate the plasma membrane localisation of the HA-rH_{3A}R and the HA-rH_{3D} isoform we subsequently performed immunocytochemistry studies using rhodamine labelled anti-HA antibodies. Plasma membrane localisation of the rhodamine-derived fluorescence was easily detected using cells expressing HA-rH_{3A}R in intact cells (Figure 2F, *upper left* panel) and only a limited intracellular fluorescence was observed in NP40 permeabilised cells (Figure 2F, *upper right* panel). In contrast, corroborating the findings

MOL # 19299

obtained by the ELISA studies, using cells transfected with cDNA encoding the HA-rH_{3D} isoform, appreciable rhodamine-derived fluorescence is only detected in permeabilised cells (Figure 2F, *bottom right* panel) and not on intact cells (Figure 2F, *bottom left* panel). Moreover, no plasma membrane localisation of the rhodamine-derived fluorescence was detected using permeabilised HA-rH_{3D} isoform expressing cells. These data indicate an intracellular localisation for the HA-rH_{3D} isoform.

Are the 6TM-rH₃ isoforms functional H₃Rs?

Radioligand binding studies - To evaluate whether the identified mRNA species for the 6TM-rH₃ isoforms code for functional H₃Rs, we transfected COS-7 cells with the cDNA encoding either the rH_{3A}R or one of the 6TM-rH₃ isoforms and evaluated corresponding membrane preparations for their ability to bind either the inverse H₃R agonist radioligand ¹²⁵IPP or the H₃R agonist radioligand [N^α-methyl-³H]histamine. Cell homogenates derived from cells expressing the rH_{3A}R bind ¹²⁵IPP with high affinity (K_D = 2.1 nM, B_{max} = 2.5 pmol/mg protein) and exhibits the expected affinities for IPP, imepip, and thioperamide (pK_b for ¹²⁵IPP 8.2±0.1, pK_i values for imepip and thioperamide 6.5±0.2 and 7.7±0.1, respectively). In contrast, we failed to detect specific ¹²⁵IPP-binding to cells transfected with cDNAs coding for any of the 6TM-rH₃ isoforms (Figure 3A). Similarly, we did not detect [N^α-methyl-³H]histamine binding to membranes of cells transfected with cDNAs encoding the 6TM-rH₃ isoforms (data not shown).

Functional assays – The H₃R couples to members of the G_{i/o} family of G-proteins to inhibit adenylyl cyclase (AC) activity and subsequently inhibits the formation of intracellular cyclic AMP (cAMP) (Leurs et al., 2005). Co-transfection of COS-7 cells with the rH_{3A}R encoding

MOL # 19299

cDNA together with pTLN121CRE, a cAMP responsive element binding protein (CREB)-responsive firefly-luciferase reporter gene, allowed us to monitor H₃R-induced modulation of forskolin-induced reporter-gene expression. In concert with the G_{i/o}-coupled nature of the H₃R (see Leurs et al., 2005), treatment of co-transfected cells with varying concentrations of the H₃R agonists immepip, R(α)-methylhistamine, and histamine results in the dose dependent inhibition of 10 μM forskolin-induced firefly-luciferase expression by approximately 60% with EC₅₀ values of approx. 2, 7, and 43 nM, respectively (Figure 3B), in rH_{3A}R-expressing cells. Under these assay conditions we do not observe constitutive activity for the rH_{3A}R as the inverse H₃R agonist thioperamide (Leurs et al., 2005) is without effect on the forskolin-induced luciferase expression (Figure 3C). While 1μM R(α)-methylhistamine potently induces signalling via the rH_{3A}R, under the same assay conditions, R(α)-methylhistamine is without effect on the forskolin-induced firefly-luciferase expression in cells co-transfected with cDNAs encoding the reporter gene and either of the 6TM-rH₃ isoforms (Figure 3D).

Is there a role for the 6TM-rH₃ isoforms?

Detection of epitope-tagged rH₃R isoforms in co-expression studies - The immunological and immunocytochemistry data obtained with the N-terminally HA-tagged HA-rH_{3D} isoform indicates poor plasma membrane expression of the rH_{3D} isoform (Figures 2E and 2F). In addition, in cells transfected with cDNA encoding either of the 6TM-rH₃ isoforms we have been unable to detect *i*) specific ¹²⁵IIPP or [N^α-methyl-³H]histamine binding (Figure 3A); *ii*) modulation of forskolin-induced transcriptional events that are otherwise modulated by rH_{3A}R activation under the same conditions. In recent years accumulating evidence suggests that some GPCRs, e.g. the GABA_B receptors (White et al., 1998) and odorant receptors (Hague et al.,

MOL # 19299

2004a), require particular protein-protein interactions to allow proper plasma membrane expression. As it seems that the 6TM-rH₃ isoforms are retained intracellularly, we therefore postulated that the additional expression of GPCRs may aid the cell surface expression of the 6TM-rH₃ isoforms. Conversely, the 6TM-rH₃ isoforms may possibly retain the co-expressed GPCRs intracellularly by acting as dominant negatives.

Do the 6TM-rH₃ isoforms interfere with cell surface expression of 7TM-rH₃Rs? – We co-transfected COS-7 cells with the cDNAs coding for the HA-rH_{3A}R and the rH_{3D} isoform. Similar to the effects of co-expression of alternative splice variants of human α_{1A} -adrenoceptors (Cogé et al., 1999), we found that the co-expression of the rH_{3D} isoform reduced the expression of the HA-rH_{3A}R at the plasma membrane. This phenomenon is observed using either an ELISA assay on intact cells or by applying immunocytochemistry techniques using a rhodamine labelled anti-HA antibody (Figures 4A and 4B, respectively).

Evaluation of ligand-binding sites upon co-expression of 7TM-H₃R and 6TM-rH₃ isoforms – To evaluate whether the loss of HA-rH_{3A}R-derived immunofluorescence at the cell surface upon co-expression of the rH_{3D} isoform also results in a loss of ligand binding sites for H₃R ligands we performed radioligand binding assays. As shown in Figure 3A, ¹²⁵IPP binding sites are detected upon the expression of 7TM-rH₃Rs (Drutel et al., 2001), such as the rH_{3A}R, whereas expression of the 6TM-rH₃ isoforms does not result in the formation of ¹²⁵IPP binding sites.

The transfection of 0.25 μ g/10⁶ cells of cDNA coding for the rH_{3A}R resulted in the expression of 2.5 pmol/mg protein ¹²⁵IPP binding sites. Co-expression of the rH_{3A}R together with the rH_{3D} isoform, however, resulted in an rH_{3D}-isoform gene-dosage dependent reduction of rH_{3A}R-

MOL # 19299

derived ^{125}I IPP binding sites (Figure 5A); the remaining ^{125}I IPP binding sites exhibit a pharmacological indistinguishable from that of the rH_{3A}R (pK_b for ^{125}I IPP 8.1 ± 0.1 , pK_i values for immpip and thioperamide 6.9 ± 0.2 and 7.6 ± 0.1 , respectively). The co-expression of the rH_{3E} or rH_{3F} isoform together with the rH_{3A}R resulted in a similar reduction of ^{125}I IPP binding sites (Figures 5B and 5C, respectively), indicating that the 6TM-rH₃ isoforms interfere with the expression of the rH_{3A}R. The maximal inhibition of ^{125}I IPP binding sites, as evaluated by a transfection of cells with an rH_{3A}R : 6TM-rH₃ isoform cDNA ratio of 1:10, is ~ 50-75% (Figures 5A, 5B, and 5C). To evaluate whether the observed inhibition of ^{125}I IPP binding-site expression is specific for the 6TM-rH₃ isoforms, we performed additional experiments in which we co-transfected cells with the same amount of rH_{3A}R cDNA in combination with various amounts of cDNA encoding the human histamine H₁ receptor (hH₁R) (Figure 5D). While the transfection of COS-7 cells with the hH₁R cDNA resulted in the formation of binding-sites for the H₁R radioligand [^3H]mepyramine with pharmacological characteristics of the hH₁R (data not shown), no specific ^{125}I IPP binding was detected in hH₁R expressing cells (Figure 5D). Co-transfection of cells with cDNAs encoding both the rH_{3A}R and the hH₁R, however, did not influence the formation of ^{125}I IPP binding sites.

Similarly to the findings with the hH₁R, expression of the rat H₂R (rH₂R) or the viral chemokine receptor from Karposi's Sarcoma herpes virus KSHV-GPCR (also known as ORF74) in COS-7 cells resulted in the formation of binding sites for the H₂R radioligand ^{125}I APT and ^{125}I -CXCL8, a radioligand for ORF74, respectively, but not in the formation of ^{125}I IPP binding sites. Co-expression of the rH_{3A}R with either the rH₂R or ORF74, however, did not affect the formation of rH_{3A}R-derived ^{125}I IPP binding sites (Figure 5E).

MOL # 19299

We also evaluated the effects of the co-expression of the rH_{3B}R and rH_{3C}R with the rH_E and rH_F isoforms, respectively, on the formation of ¹²⁵IIPP binding sites. Similar to the expression of the rH_{3A}R, expression of the rH_{3B}R or rH_{3C}R in COS-7 cells results in the formation of ¹²⁵IIPP binding sites (Drutel et al., 2001). Co-expression of the rH_{3B}R or rH_{3C}R together with either the rH_{3E} or rH_{3F} isoform resulted in an rH_{3E}- and rH_{3F}-isoform gene-dosage dependent reduction of rH_{3B}R- (Figure 5F) and rH_{3C}R- (Figure 5G) derived ¹²⁵IIPP binding sites, respectively. The maximal inhibition of ¹²⁵IIPP binding sites, as evaluated by a transfection of cells with an rH_{3B}R or rH_{3C}R : 6TM-rH₃ isoform cDNA ratio of 1:10, is ~ 50-75% (Figures 5F and 5G), similar to our findings on the co-expression of the rH_{3A}R with the 6TM-rH₃ isoforms (Figures 5A, 5B, and 5C).

Whilst the co-expression of the rH_{3A}R with the rH_{3D} isoform inhibits the formation of ¹²⁵IIPP binding sites, the remaining ¹²⁵IIPP binding sites exhibit unchanged pharmacological characteristics of the rH_{3A}R, as evidenced by its unchanged affinity for IPP (Figure 5H).

Collectively, these radioligand-binding data clearly demonstrate that the expression of the 6TM-rH₃ isoforms selectively interferes with the expression of the 7TM-rH₃Rs.

Evaluation of H₃R-ligand induced [³⁵S]GTPγS binding upon co-expression of 7TM-H₃R and 6TM-rH₃ isoforms.

Creation of rH_{3A}R-Gα fusion proteins – Since we failed to detect H₃R-agonist mediated [³⁵S]GTPγS binding to activated Gα proteins in cell membranes derived from 6TM-rH₃ isoform expressing cells (data not shown), we chose to evaluate H₃R-agonist induced [³⁵S]GTPγS binding to assess the effects of the co-expression of 6TM-rH₃ isoforms on the functionality of 7TM-rH₃Rs. To assess the effects of the co-expression of 6TM-rH₃ isoforms on the functionality

MOL # 19299

of 7TM-rH₃R_s we chose to evaluate H₃R-agonist induced [³⁵S]GTPγS binding to activated Gα proteins. To increase the sensitivity of this assay (Milligan, 2000) we created fusion proteins consisting of the rH_{3A}R fused to one of the PTX insensitive mutant rat Gα_{i/o} proteins: Gα_{i1}C³⁵¹I, Gα_{i2}C³⁵²I, Gα_{i3}C³⁵¹I, or Gα_oC³⁵¹I (creating rH_{3A}R-Gα_{o1}C³⁵¹I, rH_{3A}R-Gα_{i1}C³⁵¹I, rH_{3A}R-Gα_{i2}C³⁵²I, and rH_{3A}R-Gα_{i3}C³⁵¹I, respectively) by PCR according to Methods.

Characterisation of rH_{3A}R-Gα fusion proteins - The four different rH_{3A}R fusion proteins rH_{3A}R-Gα_{o1}C³⁵¹I, rH_{3A}R-Gα_{i1}C³⁵¹I, rH_{3A}R-Gα_{i2}C³⁵²I, and rH_{3A}R-Gα_{i3}C³⁵¹I, were subsequently characterised by ¹²⁵IPP binding assays upon their heterologous expression in COS-7 cells. Based on these studies (data not shown) we decided to continue our experiments using the rH_{3A}R-Gα_{o1}C³⁵¹I fusion protein as this fusion protein exhibited a pK_b value for ¹²⁵IPP of 8.4 ± 0.2 that corresponds to the obtained pK_b value of ¹²⁵IPP for the wild-type rH_{3A}R of 8.2 ± 0.1. Also, the affinities of the wild-type rH_{3A}R and the rH_{3A}R-Gα_{o1}C³⁵¹I fusion protein for the H₃R agonist immepip and the inverse H₃R agonist thioperamide are similar (6.5±0.2 and 7.7±0.1 *versus* 6.9±0.1 and 7.9±0.1, respectively).

Subsequently we compared the capability of the rH_{3A}R-Gα_{o1}C³⁵¹I fusion protein to mediate the inhibition of 10μM forskolin-induced activation of CRE-mediated gene transcription in COS-7 cells. We found the the rH_{3A}R-Gα_{o1}C³⁵¹I fusion protein to potently inhibit the forskolin-induced response upon activation with H₃R agonists. In concert with our findings on the wild-type rH_{3A}R, treatment of cells co-transfected with cDNAs encoding the rH_{3A}R-Gα_{o1}C³⁵¹I fusion protein and the CRE-reporter gene with varying concentrations of the H₃R agonists immepip, R(α)-methylhistamine, and histamine results in the dose dependent inhibition of 10 μM forskolin-induced firefly-luciferase expression by approximately 40% with EC₅₀ values of approx. 4, 30,

MOL # 19299

and 76 nM, respectively (Figure 6A). These data indicate that the rH_{3A}R-Gα₀₁C³⁵¹I fusion protein is fully functional and shows a rH_{3A}R pharmacology.

Co-expression of rH_{3A}R-Gα₀₁C³⁵¹I fusion proteins and the rH_{3D} isoform - Consistent with our findings on the co-expression of 7TM-rH_{3A}Rs with the 6TM-rH₃ isoforms (see Figure 5), co-expression of the rH_{3A}R-Gα₀₁C³⁵¹I fusion protein together with the rH_{3D} isoform, results in an rH_{3D}-isoform gene-dosage dependent reduction of rH_{3A}R-Gα₀₁C³⁵¹I fusion protein -derived ¹²⁵IPP binding sites (Figure 6B), and the remaining ¹²⁵IPP binding sites exhibit an rH_{3A}R-Gα₀₁C³⁵¹I-like pharmacological profile (pK_b for ¹²⁵IPP 8.5±0.1, pK_i values for immpip and thioperamide 7.0±0.2 and 7.6±0.1, respectively). The maximal inhibition of rH_{3A}R-Gα₀₁C³⁵¹I-derived ¹²⁵IPP binding sites, as evaluated by a transfection of cells with an rH_{3A}R-Gα₀₁ : rH_{3D} isoform cDNA ratio of 1:10, is ~ 65% (Figure 6B).

We subsequently assessed the influence of co-expression of the rH_{3D} isoform on the [³⁵S]GTPγS binding induced by agonist-mediated activation of co-expressed rH_{3A}R-Gα₀₁C³⁵¹I fusion proteins. The H₃R agonist immpip (1 μM) resulted in a robust stimulation of [³⁵S]GTPγS binding in rH_{3A}R-Gα₀₁C³⁵¹I expressing cells, that was inhibited by co-incubation with 1 μM of the inverse H₃R agonist thioperamide (Figure 6C). Under the assay conditions used, we could not detect significant thioperamide-mediated inhibition of basal rH_{3A}R-Gα₀₁C³⁵¹I mediated [³⁵S]GTPγS binding, indicating that we could not detect constitutive rH_{3A}R-Gα₀₁C³⁵¹I activity. The 1 μM immpip-induced [³⁵S]GTPγS binding was inhibited by 70 % by co-expression of the rH_{3A}R-Gα₀₁C³⁵¹I fusion protein with the rH_{3D} isoform (Figure 6C). The 6TM-rH₃ isoforms

MOL # 19299

themselves did not mediate changes in [³⁵S]GTPγS binding upon incubation with H₃R ligands (data not shown).

Can rH₃Rs form homo-oligomers?

In view of the emerging concept of GPCR dimerisation that is now well documented in literature (see e.g. Pflieger and Eidne, 2005 for a review), we speculated that the 6TM-rH₃ isoforms might interfere with the cell surface expression of 7TM-rH₃ receptors through dimerisation.

Previously we described the generation of anti-rH_{3C} 268-277Cys antibodies (Shenton et al., 2005), which based on immunoblotting, selectively recognize both the rH_{3A}R and rH_{3C}R isoform, but not the rH_{3B}R isoform expressed in HEK 293 cells. Wild-type rH_{3A}R expressing cells were collected and subjected to crosslinking with varying amounts of the cell permeable cross-linker bis(sulfosuccinimidyl)suberate (BS3) prior to resolving the samples using SDS-PAGE. Immunoblotting with anti-H_{3C} 268-277Cys antibody yielded three major protein species (M_r 90,000, M_r 135,000 and approx. M_r 200,000, respectively), corresponding well to putative dimeric, trimeric and tetrameric rH_{3A}R oligomers, respectively (Figure 7, lanes 1-3). Performing similar experiments using native rat brain tissue, the major species observed is a coincident M_r 90,000 species (Figure 7, lane 4). Interestingly, a recombinant putative monomeric M_r 47,000 species was clearly observed, which was barely detectable in the native forebrain preparation. Higher crosslinker concentrations yielded >200,000 species for both recombinant and native H₃R preparations (Shenton et al., 2005).

We have previously successfully used the *time-resolved* Fluorescent Resonance Energy Transfer (*tr*-FRET) fluorescence (665-nm emission after excitation at 320 nm) for the detection of hH₁R

MOL # 19299

dimerisation using epitope tagged hH₁Rs and fluorescently labeled antibodies recognizing the N-terminally epitope-tagged receptors (Bakker et al., 2004a). We have used this approach to confirm the formation of oligomerisation of rH₃Rs.

tr-FRET fluorescence results obtained with the different samples are shown in Figure 7B. A clear specific *tr*-FRET signal is observed using live cells expressing the HA-rH_{3A}Rs. The data is presented as the *tr*-FRET that is observed using HA-rH_{3A}R expressing cells that have been incubated with both anti-HA-Eu³⁺ and anti-HA-allophycocyanin antibodies *versus* the *tr*-FRET that is observed using a mix of two populations of HA-rH_{3A}R expressing cells that prior to mixing were independently incubated with either of the two antibodies. The increased *tr*-FRET signal can only be explained due to the resonance energy transfer from anti-HA-Eu³⁺ antibodies bound to HA-rH_{3A}Rs to anti-HA-allophycocyanin antibodies bound to HA-rH_{3A}Rs, indicative of the formation of rH_{3A}R multimers in living cells.

Modulation of rH_{3AD} and rH_{3DEF} isoform-specific mRNAs in rat brain after delivery of a systemic convulsant.

Previously we have successfully used specific oligonucleotide probes to characterise the 7TM-rH₃R mRNA expression in the rat brain (Drutel et al., 2001). To evaluate the CNS expression of the 6TM-rH₃ isoforms we have designed domain specific probes. We have used one probe specific for the C-terminus present in the 6TM-rH₃ isoforms, and, as a comparison, we have also performed studies using a oligonucleotide probe specific for the (full length) third intracellular loop of the rH_{3A}R, which is also present in the rH_{3D} isoform (but not any of the other rH₃ isoforms identified to date; Figure 8A).

MOL # 19299

Significant increases in mRNA expression levels of H₃R isoforms with full length third intracellular loop (detected using probe H_{3AD}) were observed in layers II-VIb of cortex (48h post-injection), caudate putamen (48h post-injection), piriform cortex (48h post-injection), and CA1 region of the hippocampus (24h post-injection) (Figure 8B) after PTZ. Figure 8C illustrates mRNA expression levels and differences for H_{3A} and H_{3D} isoforms in representative sections from control and 48h post-injection animals.

In contrast, decreases in mRNA expression pattern of 6TM-rH₃ isoforms (detected using probe H_{3DEF}) were observed in layers II-VIb of cortex (6h post-injection), piriform cortex (6h, 24h, and 48h post-injection), CA1 region of the hippocampus (24h post-injection), and CA3 region of the hippocampus (24h post-injection) (Figure 8D). Figure 8E shows mRNA expression patterns and differences for 6TM-rH₃ isoforms in representative sections from control and 24h post-injection animals.

MOL # 19299

DISCUSSION

Our search for additional alternative splice variants of the rH₃R resulted in the identification of three mRNAs coding for heretofore uncharacterised rH₃ isoforms. In contrast to the known functional H₃Rs, sequence analysis of these newly identified isoforms reveals that an additional splicing event occurs within a region corresponding to TM6, resulting in isoforms with an alternative C-terminal domain and isoforms that are predicted to possess only 6 TMs. The mRNAs encoding these 6TM-rH₃ isoforms are expressed in the rat brain with a distribution pattern that is similar to the previously identified functional 7TM-rH₃Rs (Drutel et al., 2001). While there may be differences in the rate of synthesis, the inherent stability, and the rate of degradation of the various H₃ isoforms resulting in differences in their expression levels, extensive analysis of the 6TM-rH₃ isoforms through heterologous expression studies, however, failed to identify any ligand-binding and functional signalling events modulated by these 6TM-rH₃ isoforms. The 6TM-rH₃ isoforms appear to be localized intracellularly, and succeeding studies revealed the ability of the 6TM-rH₃ isoforms to interfere with the cell surface expression and subsequent signalling of the previously identified 7TM-rH₃ isoforms, thus acting as dominant negatives.

An increasing number of GPCRs have been shown to exist as oligomeric complexes (see e.g. Pflieger and Eidne, 2005 for a review), which are thought to be formed early during biosynthesis (Terrillon et al., 2003). In this study we show that also the rH_{3A}R is present as dimers or higher order oligomeric complexes both in transfected cells and in rat brain. The oligomerization of GPCRs during biosynthesis and maturation appears crucial for proper exportation of receptors to

MOL # 19299

the plasma membrane (reviewed in Bulenger et al., 2005). The co-expression and formation of heterodimeric β_2 -ARs (Hague et al., 2004a) aids for instance the cell surface trafficking of olfactory GPCRs that are otherwise retained and degraded in the ER (Lu et al., 2003; Lu et al., 2004), as well as of the α_{1D} -AR that normally is trafficked poorly to the cell surface (Uberti et al., 2004). The co-expression of differentially spliced GPCR variants may also aid the cell-surface expression, as shown for instance by the co-expression of the α_{1D} -AR with α_{1B} -ARs (Hague et al., 2004b). In contrast, certain alternatively spliced variants of for instance the α_{1A} -AR (Cogé et al., 1999), the calcitonin receptor (Seck et al., 2003) and the dopamine D₃ receptor (Karpa et al., 2000) appear to dimerise with their cognate full-length receptors and impede their cell surface expression due to mislocalization to an intracellular compartment. The co-expression of the herein described 6TM-rH₃ isoforms not only reduced cell surface expression of the 7TM-rH₃Rs, but consequently also resulted in a reduced 7TM-rH₃R mediated signalling. Our data are therefore consistent with the reported findings on the co-expression of N-terminal truncated, dominant negative mutants and wild-type V₂ receptors, which results in the formation of heterodimers and reduced agonist binding, signal transduction and cell-surface trafficking of the full-length V₂ receptor (Zhu and Wess, 1998). Similar to our findings on the 6TM-rH₃ isoforms, mutants of the α_2 -AR (Zhou et al.), vasopressin V₂ (Zhu and Wess, 1998), dopamine D₂ (Lee et al., 2000), chemokine receptor CCR5 (Benkirane et al., 1997; Blanpain et al., 2000; Chelli and Alizon, 2001), gonadotropin-releasing hormone (GnRH) receptor (Brothers et al., 2004), and the platelet-activating factor (Le Gouill et al., 1999) receptors also impede the cell surface expression of their co-expressed wild-type counterparts, thus exhibiting *trans*-dominant negative effects on wild-type receptor expression (Benkirane et al., 1997; Brothers et al., 2004; Chelli and Alizon, 2001), most likely through dimerization. It appears most likely that the 6TM-rH₃

MOL # 19299

isoforms interfere with the functional expression of the 7TM-rH₃Rs through hetero-dimerization. Although direct hetero-dimerization of the 6TM-rH₃ isoforms with the 7TM-rH₃Rs remains to be established, we have shown the rH_{3A}R to be constitutively expressed as a dimeric receptor in the brain as well as upon heterologous expression.

GPCRs have been found to interact with accessory proteins which can be critical for their biogenesis (see also Bermak and Zhou, 2001 for a review; Metherell et al., 2005). A conserved F(X)₆LL motif, which is suggested to be important for the proper GPCR folding and subsequent export from the ER (Duvernay et al., 2004), is also present in the C-terminal domain of the 7TM-rH₃Rs, but is lacking in the 6TM-rH₃ isoforms. Mutations in regions overlapping the F(X)₆LL motif in the dopamine D₁ receptor resulted in ER retention of the mutant receptor and loss of cell surface expression, and subsequent studies revealed that this region is important for a interactions with a specific ER-membrane-associated protein that regulates transport of GPCRs (Bermak et al., 2001). Intriguingly, instead of the F(X)₆LL motif, the 6TM-rH₃ isoforms possess an RXR ER retention signal. Collectively, these data suggest that the 6TM-rH₃ isoforms lack protein-protein interactions with specific accessory proteins in the ER that are required for cell-surface expression. Although the localisation of the 6TM-rH₃ isoforms within the ER appears likely, this needs to be verified by future experiments. Nonetheless, the findings on GPR30 as an intracellular GPCR (Revankar et al., 2005) points out that the 6TM-rH₃ isoforms may well have yet undiscovered intracellular functions in addition to their capability to retain the 7TM-rH₃Rs intracellularly.

On the one hand, the 6TM-rH₃ splice variants may act as ‘antichaperones’ inhibiting specific chaperones’ activities or preventing their access to the 7TM-rH₃Rs. Alternatively, the association of the 6TM-rH₃ isoforms with the 7TM-rH₃R isoforms in the ER may actively unfold or result in

MOL # 19299

the misfolding of the protein complex. As we find the rH_{3D} isoform not to interfere with the cell surface expression of unrelated GPCRs, it seems unlikely the 6TM-rH₃ isoforms act through blocking either the ER or Golgi, or to promote ER-associated protein degradation. The precise mechanism underlying the action of the newly identified isoforms, however, remains unknown. Our data suggests that the regulation of the alternative rH_{3R} mRNA splicing is a new and effective means for the regulation of H_{3R} signalling. Functional (including constitutive) H_{3R} activity may be regulated through the regulation of the splicing-events underlying the occurrence of the various H_{3R} isoforms. Interestingly, several cell signalling pathways, including the MAPK pathway, regulate mRNA splicing (reviewed in Shin and Manley, 2004). Intriguingly, the H_{3R} activates the MAPK pathway (Drutel et al., 2001; Giovannini et al., 2003), arguing for the possibility of activation of splicing factors and hence, an autoregulation of the H_{3R} activity.

Our studies also show that the expression pattern of the 7TM-rH_{3R}s and the 6TM-rH₃ isoforms overlaps substantially in rat brain. Moreover, PTZ-induced seizures result in suppression of 6TM-rH₃ (probe H_{3DEF}) isoform mRNAs in particular brain regions while mRNA levels of the isoforms with the full third intracellular loop (probe H_{3AD}) are increased. A characteristic transient and short-living increase in the mRNA for the full-length third intracellular loop (probe H_{3AD}), hippocampal CA_{3c} area, followed by piriform cortex, amygdala and hippocampal CA₁ area is observed after systemic injection of kainic acid, a model of temporal lobe epilepsy (Lintunen et al., 2005), indicating a spatiotemporal correlation to progressing neuronal damage in this model of temporal epilepsy. Previous studies on PTZ have indicated damaged neurons in the rostral limbic cortex (both the orbital, agranular insular and pre-limbic), the lateral hypothalamus (in the vicinity of the rostral medial forebrain bundle), the bed nucleus of the stria

MOL # 19299

terminalis, the claustrum, the hippocampal formation (CA3 and entorhinal cortex) and lateral thalamic nuclei 50 min post injection (Ben-Ari et al., 1981). The increases in H₃R mRNA with full third intracellular loop as observed in this study after PTZ were observed significantly later than the reported damage begins (Ben-Ari et al., 1981), in agreement with the concept that the mechanisms of neuronal damage following kainic acid and PTZ are different. Although the piriform cortex has not been reported to suffer significant damage after PTZ (Ben-Ari et al., 1981), it seems not to be only a primary sensory area but because of its neuronal organization and associative fiber system may also be involved in the pathological mechanisms leading to seizures (Löscher and Ebert, 1996). Of the areas studied here, the piriform cortex showed a sustained decline in 6TM-rH₃ mRNA expression. Interestingly, we observed a significant transient increase in H₃R radioligand binding in piriform cortex at 6 h after PTZ concomitantly with the decline of H_{3DEF} isoform mRNAs (data not shown). However, a similar strong correlation was not found in all areas where smaller changes were seen, suggesting that other factors in addition to mRNA ratios may affect receptor binding. The high susceptibility for induction of seizures by chemical or electrical stimulation and various studies addressing its role in seizure generation suggest that the piriform cortex can also function as an amplifier region to increase and propagate seizure activity induced in other limbic regions (Löscher and Ebert, 1996). Increased H₃R activity (e.g., expression and translation) in this region could result in decreased glutamate release (Brown and Haas, 1999; Molina-Hernandez et al., 2001), as glutamatergic neurons exist in the piriform cortex (Riba-Bosch and Perez-Clausell, 2004), for control of overall neuronal activity in the region.

The abundance of mRNA coding for the 6TM-rH₃ isoforms suggest that its production may have important biological implications. For example, in addition to its ability to interfere with cell

MOL # 19299

surface expression of functional rH₃Rs, which may arise from modification of the stability of the mRNA encoding functional 7TM-rH₃Rs, the 6TM-rH₃ isoform mRNAs might encode proteins with yet unidentified functions. Further analysis of the alternatively spliced products of the H₃R gene is required to elucidate their biological significance.

In conclusion, we have identified three additional splice variants of the rH₃R. The mRNAs of these isoforms are abundantly expressed in the brain and the expression pattern largely overlaps with that of the known rH_{3A-C}R isoforms. Analysis of the sequence of these rH_{3D}, rH_{3E}, and rH_{3F} isoforms reveals these isoforms to consist of 6TM domains. The 6TM-rH₃ isoforms are retained intracellularly upon heterologous expression, and in subsequent pharmacological analysis studies we could not detect any ligand binding or functional activity for these 6TM-rH₃ isoforms. The 6TM-rH₃ isoforms, however, selectively impede cell surface expression of the functional 7TM-rH₃Rs. Moreover, the mRNA levels of the rH₃ isoforms in rat brain are modulated by treatment with the convulsant PTZ. Although, the functional significance and possible roles of these 6TM-rH₃ isoforms in (patho-)physiology remain to be established, these findings provide novel insight in the regulation of the histaminergic system in the brain.

MOL # 19299

ACKNOWLEDGMENTS

This paper is dedicated to Dr. Art A. Hancock, who sadly passed away in November last year. Dr. Hancock was a great scientist with a warm and generous personality. Under his inspired leadership Abbott Laboratories has made many seminal contributions to the field of H₃ receptors. We thank Sarina M. Meusburger, Franca di Summa, Kim Retra, and José Antonio Arias-Montaña for expert assistance.

MOL # 19299

REFERENCES

- Bakker RA (2004) Histamine H₃-receptor isoforms. *Inflamm Res* **53**(10):509-516.
- Bakker RA, Dees G, Carrillo JJ, Booth RG, López-Gimenez JF, Milligan G, Strange PG and Leurs R (2004a) Domain swapping in the human histamine H₁ receptor. *J Pharmacol Exp Ther* **311**:131-138.
- Bakker RA, Weiner DM, ter Laak T, Beuming T, Zuiderveld OP, Edelbroek M, Hacksell U, Timmerman H, Brann MR and Leurs R (2004b) 8*R*-lisuride is a potent stereospecific histamine H₁-receptor partial agonist. *Mol Pharmacol* **65**(3):538-549.
- Ben-Ari Y, Tremblay E, Riche D, Ghilini G and Naquet R (1981) Electrographic, clinical and pathological alterations following systemic administration of kainic acid, bicuculline or pentetrazole: metabolic mapping using the deoxyglucose method with special reference to the pathology of epilepsy. *Neuroscience* **6**(7):1361-1391.
- Benkirane M, Jin DY, Chun RF, Koup RA and Jeang KT (1997) Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by *ccr5*Δ32. *J Biol Chem* **272**(49):30603-30606.
- Bermak JC, Li M, Bullock C and Zhou QY (2001) Regulation of transport of the dopamine D1 receptor by a new membrane-associated ER protein. *Nat Cell Biol* **3**(5):492-498.
- Bermak JC and Zhou QY (2001) Accessory proteins in the biogenesis of G protein-coupled receptors. *Mol Interv* **1**(5):282-287.
- Blanpain C, Lee B, Tackoen M, Puffer B, Boom A, Libert F, Sharron M, Wittamer V, Vassart G, Doms RW and Parmentier M (2000) Multiple nonfunctional alleles of CCR5 are frequent in various human populations. *Blood* **96**(5):1638-1645.

MOL # 19299

- Brothers SP, Cornea A, Janovick JA and Conn PM (2004) Human loss-of-function gonadotropin-releasing hormone receptor mutants retain wild-type receptors in the endoplasmic reticulum: molecular basis of the dominant-negative effect. *Mol Endocrinol* **18**(7):1787-1797.
- Brown RE and Haas HL (1999) On the mechanism of histaminergic inhibition of glutamate release in the rat dentate gyrus. *J Physiol* **515** (Pt 3):777-786.
- Bulenger S, Marullo S and Bouvier M (2005) Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. *Trends in Pharmacological Sciences* **26**(3):131-137.
- Chazot PL, Hann V, Wilson C, Lees G and Thompson CL (2001) Immunological identification of the mammalian H₃ histamine receptor in the mouse brain. *Neuroreport* **12**(2):259-262.
- Chelli M and Alizon M (2001) Determinants of the *trans*-dominant negative effect of truncated forms of the CCR5 chemokine receptor. *J Biol Chem* **276**(50):46975-46982.
- Cogé F, Guénin SP, Audinot V, Renouard-Try A, Beauverger P, Macia C, Ouvry C, Nagel N, Rique H, Boutin JA and Galizzi JP (2001) Genomic organization and characterization of splice variants of the human histamine H₃ receptor. *Biochem J* **355**(Pt 2):279-288.
- Cogé F, Guenin SP, Renouard-Try A, Rique H, Ouvry C, Fabry N, Beauverger P, Nicolas JP, Galizzi JP, Boutin JA and Canet E (1999) Truncated isoforms inhibit [³H]prazosin binding and cellular trafficking of native human α_{1A} -adrenoceptors. *Biochem J* **343** Pt 1:231-239.
- Drutel G, Peitsaro N, Karlstedt K, Wieland K, Smit MJ, Timmerman H, Panula P and Leurs R (2001) Identification of rat H₃ receptor isoforms with different brain expression and signaling properties. *Mol Pharmacol* **59**(1):1-8.

MOL # 19299

Duvernay MT, Zhou F and Wu G (2004) A conserved motif for the transport of G protein-coupled receptors from the endoplasmic reticulum to the cell surface. *J Biol Chem* **279**(29):30741-30750.

Giovannini MG, Efoudebe M, Passani MB, Baldi E, Bucherelli C, Giachi F, Corradetti R and Blandina P (2003) Improvement in fear memory by histamine-elicited ERK2 activation in hippocampal CA3 cells. *J Neurosci* **23**(27):9016-9023.

Hague C, Uberti MA, Chen Z, Bush CF, Jones SV, Ressler KJ, Hall RA and Minneman KP (2004a) Olfactory receptor surface expression is driven by association with the β_2 -adrenergic receptor. *Proc Natl Acad Sci U S A* **101**(37):13672-13676.

Hague C, Uberti MA, Chen Z, Hall RA and Minneman KP (2004b) Cell surface expression of α_{1D} -adrenergic receptors is controlled by heterodimerization with α_{1B} -adrenergic receptors. *J Biol Chem* **279**(15):15541-15549.

Hawrylyshyn KA, Michelotti GA, Coge F, Guenin SP and Schwinn DA (2004) Update on human alpha1-adrenoceptor subtype signaling and genomic organization. *Trends Pharmacol Sci* **25**(9):449-455.

Karpa KD, Lin R, Kabbani N and Levenson R (2000) The dopamine D3 receptor interacts with itself and the truncated D3 splice variant d3nf: D3-D3nf interaction causes mislocalization of D3 receptors. *Mol Pharmacol* **58**(4):677-683.

Kilpatrick GJ, Dautzenberg FM, Martin GR and Eglen RM (1999) 7TM receptors: the splicing on the cake. *Trends Pharmacol Sci* **20**(7):294-301.

Le Gouill C, Parent JL, Caron CA, Gaudreau R, Volkov L, Rola-Pleszczynski M and Stankova J (1999) Selective modulation of wild type receptor functions by mutants of G-protein-coupled receptors. *J Biol Chem* **274**(18):12548-12554.

MOL # 19299

- Lee SP, O'Dowd BF, Ng GY, Varghese G, Akil H, Mansour A, Nguyen T and George SR (2000) Inhibition of cell surface expression by mutant receptors demonstrates that D2 dopamine receptors exist as oligomers in the cell. *Mol Pharmacol* **58**(1):120-128.
- Leurs R, Bakker RA, Timmerman H and de Esch IJ (2005) The histamine H₃ receptor: from gene cloning to H₃ receptor drugs. *Nat Rev Drug Discov* **4**(2):107-120.
- Lintunen M, Sallmen T, Karlstedt K and Panula P (2005) Transient changes in the limbic histaminergic system after systemic kainic acid-induced seizures. *Neurobiol Dis* **20**(1):155-169.
- Löscher W and Ebert U (1996) The role of the piriform cortex in kindling. *Prog Neurobiol* **50**(5-6):427-481.
- Lu M, Echeverri F and Moyer BD (2003) Endoplasmic reticulum retention, degradation, and aggregation of olfactory G-protein coupled receptors. *Traffic* **4**(6):416-433.
- Lu M, Staszewski L, Echeverri F, Xu H and Moyer BD (2004) Endoplasmic reticulum degradation impedes olfactory G-protein coupled receptor functional expression. *BMC Cell Biol* **5**(1):34.
- Metherell LA, Chapple JP, Cooray S, David A, Becker C, Ruschendorf F, Naville D, Begeot M, Khoo B, Nurnberg P, Huebner A, Cheetham ME and Clark AJ (2005) Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2. *Nat Genet* **37**(2):166-170.
- Milligan G (2000) Insights into ligand pharmacology using receptor-G-protein fusion proteins. *Trends in Pharmacological Sciences* **21**(1):24-28.

MOL # 19299

- Molina-Hernandez A, Nunez A, Sierra JJ and Arias-Montano JA (2001) Histamine H₃ receptor activation inhibits glutamate release from rat striatal synaptosomes. *Neuropharmacology* **41**(8):928-934.
- Morisset S, Sasse A, Gbahou F, Héron A, Ligneau X, Tardivel-Lacombe J, Schwartz JC and Arrang JM (2001) The rat H₃ receptor: gene organization and multiple isoforms. *Biochem Biophys Res Commun* **280**(1):75-80.
- Pfleger KD and Eidne KA (2005) Monitoring the formation of dynamic G-protein-coupled receptor-protein complexes in living cells. *Biochem J* **385**(Pt 3):625-637.
- Revankar CM, Cimino DF, Sklar LA, Arterburn JB and Prossnitz ER (2005) A transmembrane intracellular estrogen receptor mediates rapid cell signaling. *Science* **307**(5715):1625-1630.
- Riba-Bosch A and Perez-Clausell J (2004) Response to kainic acid injections: changes in staining for zinc, FOS, cell death and glial response in the rat forebrain. *Neuroscience* **125**(3):803-818.
- Schmauss C, Haroutunian V, Davis KL and Davidson M (1993) Selective loss of dopamine D₃-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. *Proc Natl Acad Sci U S A* **90**(19):8942-8946.
- Seck T, Baron R and Horne WC (2003) The alternatively spliced Δ e13 transcript of the rabbit calcitonin receptor dimerizes with the C1a isoform and inhibits its surface expression. *J Biol Chem* **278**(25):23085-23093.
- Shenton FC, Hann V and Chazot PL (2005) Evidence for native and cloned H₃ histamine receptor higher oligomers. *Inflammation Res* **54**:S48-S49.

MOL # 19299

Shin C and Manley JL (2004) Cell signalling and the control of pre-mRNA splicing. *Nat Rev Mol Cell Biol* **5**(9):727-738.

Smit MJ, Verzijl D, Casarosa P, Navis M, Timmerman H and Leurs R (2002) Kaposi's sarcoma-associated herpesvirus-encoded G protein-coupled receptor ORF74 constitutively activates p44/p42 MAPK and Akt via G_i and phospholipase C-dependent signaling pathways. *J Virol* **76**(4):1744-1752.

Terrillon S, Durroux T, Mouillac B, Breit A, Ayoub MA, Taulan M, Jockers R, Barberis C and Bouvier M (2003) Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. *Mol Endocrinol* **17**(4):677-691.

Uberti MA, Hague C, Oller H, Minneman KP and Hall RA (2005) Heterodimerization with β_2 -adrenergic receptors promotes surface expression and functional activity of α_{1D} -adrenergic receptors. *J Pharmacol Exp Ther* **313**(1):16-23.

White JH, Wise A, Main MJ, Green A, Fraser NJ, Disney GH, Barnes AA, Emson P, Foord SM and Marshall FH (1998) Heterodimerization is required for the formation of a functional GABA_B receptor. *Nature* **396**(6712):679-682.

Zhou F, Filipeanu CM, Duvernay MT and Wu G (2006) Cell-surface targeting of α_2 -adrenergic receptors -- Inhibition by a transport deficient mutant through dimerization. *Cellular Signalling* **18**(3):318-327.

Zhu X and Wess J (1998) Truncated V₂ vasopressin receptors as negative regulators of wild-type V₂ receptor function. *Biochemistry* **37**(45):15773-15784.

MOL # 19299

FOOTNOTES

a) Unnamed footnotes:

* Financial support: *RL* is a recipient of a PIONIER award of the Technology Foundation (STW) of the Netherlands Foundation of Scientific Research (NWO). Supported by the Academy of Finland (*PP*), and the Finnish Foundation for Alcohol Studies (*PP*, *ML* and *AL*).

§ Current addresses: Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Metabolic Diseases, 88397 Biberach, Germany (*RAB*); Galapagos Genomics BV, 2333 CN Leiden, The Netherlands (*MH*); and Institut François Magendie, 33077 Bordeaux cedex, MC Université Bx2, France (*GD*).

b) Reprint requests to: Dr. R. Leurs, Leiden/Amsterdam Center for Drug Research, Department of Medicinal Chemistry, Vrije Universiteit Amsterdam, De Boelelaan 1083, 1081HV Amsterdam, The Netherlands. Tel: ++31-20-5987600. Fax: ++31-20-5987610. E-mail: r.leurs@few.vu.nl.

c) Numbered footnotes: *none*.

MOL # 19299

FIGURE LEGENDS

Figure 1. Sequence alignment of rH₃R isoforms and genomic organisation of the rH₃R gene. *A*, Amino-acid sequence alignment of various rH₃R isoforms. The rH_{3B}R and rH_{3C}R isoforms exhibit amino-acid deletions in the third intracellular loop of the rH₃R protein compared to the full length rH_{3A}R. The rH_{3D}, rH_{3E}, and rH_{3F} isoforms differ from the rH_{3A}R, rH_{3B}R and rH_{3C}R isoforms, respectively, in an alternative C-terminal domain as a result of an additional splicing event (see Figure 1*A*). Indicated above the amino acids are the seven transmembrane domains as they are found for the rH_{3A}R, rH_{3B}R and rH_{3C}R isoforms (TM1 through TM7). *B*, Diagram of the exon/intron structure of the rat H₃R gene on chromosome 3 (Genbank accession number NM_053506.1 (GI:16758263)) and the resulting amino acid (aa) sequences found in rH_{3A-C} receptors and rH_{3D-E} isoforms generated by retention/deletion of the pseudo-introns. The exon/intron junctions within the rH₃R gene are indicated in bold (**GT** and **AG**), whereas the codon that corresponds to the cysteine (C) found in the rH_{3D-F} isoforms (formed by TG and T) is underlined. For simplicity, only part of the exon/intron structure of the rat H₃R gene and of the rH₃R gene sequence is shown (as indicated by //). See (Morisset et al., 2001) for an overview of the exon/intron structure of the rH₃R gene corresponding to the two presumably non-functional H₃R isoforms, H_{3(nf1)} and H_{3(nf2)}, and the four previously described functional shorter isoforms, rH_{3B} (rH₃₍₄₁₃₎), rH₃₍₄₁₀₎, and rH_{3C} (rH₃₍₃₉₇₎).

Figure 2. Topology of the rH₃R isoforms. Prediction of the topology of the rH_{3A}R (*A*) versus the rH_{3D}R (*B*), as predicted by the TMHMM Server at the Center for Biological Sequence Analysis, Technical University of Denmark, DTU (<http://www.cbs.dtu.dk/services/TMHMM/>). Indicated

MOL # 19299

by the solid line are the probabilities for localisation on the extracellular side (outside); the probabilities of localisation on the intracellular side (Inside) are indicated by the dotted lines. The probability for transmembrane (TM) domains are indicated by the filled areas. From these two plots it can be deduced that seven TM domains are predicted for the rH_{3A}R while for the rH_{3D}R only six TM domains are predicted, as indicated above the graphs. *C*, Graphical representation of the topology of the rH_{3A}, rH_{3B}, and rH_{3C} receptors, *versus* the rH_{3D}, rH_{3E}, and rH_{3F} isoforms (*D*). In contrast to the rH_{3A}, rH_{3B}, and rH_{3C} receptors, the rH_{3D}, rH_{3E}, and rH_{3F} isoforms are predicted to possess an extracellular C-terminal domain. Also indicated in *C* and *D* are the variations in the third intracellular loop between the isoforms. *E* and *F*, Immunological detection of N-terminally HA-tagged rH_{3A}Rs (HA-rH_{3A}) and the N-terminally HA-tagged rH_{3D} isoform (HA-rH_{3D}) on transfected COS-7 cells. *E*, Detection of HA-rH_{3A}Rs and the HA-rH_{3D} isoform in intact cells *versus* cells that have been permeabilised using 0.5% NP-40 in an ELISA assay. *F*, Immunocytochemical detection of HA-tagged rH_{3R} isoforms using a rhodamine conjugated antibody directed against the HA-tag. Detection of HA-rH_{3A}Rs on intact COS-7 cells (upper panel, left) and in permeabilised cells (upper panel, right). Detection of the HA-rH_{3D} isoform on intact cells (bottom panel, left) and in permeabilised cells (bottom panel, right).

Figure 3. Functional analysis of the rH_{3A}R and the rH_{3D} isoform upon transient transfection of their corresponding cDNAs in COS-7 cells. *A*, Transfection of cells with rH_{3A}R coding cDNA (pcDEF₃rH_{3A}R; 5 µg/10⁶ cells) resulted in the expression of ¹²⁵I-PP binding sites, whereas no specific ¹²⁵I-PP binding was detected to membrane fractions of cells transfected with an equal amount of cDNA coding for either the rH_{3D}, rH_{3E}, or rH_{3F} isoform. *B*, Dose dependent modulation of 10 µM forskolin induced responses by histamine, immpip, and R(α)-

MOL # 19299

methylhistamine using COS-7 cells co-transfected with $5 \mu\text{g}/10^6$ cells of both pcDEF₃rH_{3A}R and a CREB-responsive firefly-luciferase reporter gene (pTLNC121CRE). *C*, Modulation of forskolin ($10 \mu\text{M}$) induced responses by $10 \mu\text{M}$ of histamine, R(α)-methylhistamine (R α MH), and thioperamide using cells transfected with both pcDEF₃rH_{3A}R and pTLNC121CRE. The forskolin induced responses are set to 100% as indicated by “control”. *D*, Effects of $10 \mu\text{M}$ R(α)-methylhistamine on forskolin ($10 \mu\text{M}$) induced responses using cells co-transfected with either pcDEF₃rH_{3A}R, pcDEF₃rH_{3D}, pcDEF₃rH_{3E}, or pcDEF₃rH_{3F}, and pTLN121CRE. The forskolin induced responses are set to 100% as indicated by the dashed line.

Figure 4. Immunological detection of N-terminally HA-tagged rH_{3A}Rs (HA-rH_{3A}) on COS-7 cells co-transfected with cDNA coding for HA-rH_{3A} receptors and the N-terminally HA-tagged rH_{3D} isoform (HA-rH_{3D}). *A*, Effects of the co-transfection of pcDEF₃rH_{3D} on the detection of HA-rH_{3A}Rs on intact cells using an ELISA assay. *B*, Immunocytochemical detection of HA-rH_{3A}Rs using a rhodamine conjugated antibody directed against the HA-tag. Detection of HA-rH_{3A}Rs on intact COS-7 cells (upper panel, left) and in permeabilised cells (upper panel, right), and effects of co-transfection cells with both pcDEF₃-HA-rH_{3A} and pcDEF₃rH_{3D} on the detection of the HA-rH_{3A}Rs on intact cells (bottom panel, left) and in permeabilised cells (bottom panel, right). Control slides of cells transfected with N-terminally HA-epitope tagged H₃ isoforms that did not receive the primary antibody or of untransfected cells showed no appreciable staining.

Figure 5. Effects of co-transfection of cDNA coding for rH₃R isoforms on the expression of ¹²⁵I-IPP binding sites. Evaluation of the effects of co-transfection of either $0.25 \mu\text{g}/10^6$ cells of pcDEF₃rH_{3A}R (*A*, *B*, *C*, *D*, and *E*), pcDEF₃rH_{3B}R (*F*), or pcDEF₃rH_{3C}R (*G*) together with varying

MOL # 19299

amounts (0 - 2.5 $\mu\text{g}/10^6$ cells) of either pcDEF₃rH_{3D} (*A*), pcDEF₃rH_{3E} (*B*, and *F*), pcDEF₃rH_{3F} (*C*, and *G*), pcDEF₃hH₁ (*D*), pcDEF₃rH_{2R} (*E*), or pcDEF₃ORF74 (*E*) on the relative number of expressed ¹²⁵I-IPP binding sites. *H*, Evaluation of the effects of co-transfection of pcDEF₃rH_{3AR} (0.25 $\mu\text{g}/10^6$ cells) together with 2.5 $\mu\text{g}/10^6$ cells of either pcDEF₃rH_{3D} (○) or pcDEF₃hH₁ (●) on the ability of IPP to displace ¹²⁵I-IPP bound to expressed ¹²⁵I-IPP binding sites (homologous displacement).

Also shown in *E* are the effects of the transfection of 2.5 $\mu\text{g}/10^6$ cells of either pcDEF₃rH_{3AR}, pcDEF₃rH_{2R}, pcDEF₃ORF74, or pcDEF₃rH_{3D} alone on the expression of ¹²⁵I-IPP binding sites. The proper expression in COS-7 cells of the hH₁R, the rH_{2R}, and ORF74 was confirmed using [³H]mepyramine, ¹²⁵I-APT, and ¹²⁵I-CXCL8 binding assays, respectively (data not shown). In each condition the total amount of cDNA has been kept constant using pcDEF₃.

Figure 6. Effects of co-transfection of the rH_{3D} isoform on the function of the rH_{3AR}. *A*, Dose dependent modulation of 10 μM forskolin induced responses by histamine, immpip, and R(α)-methylhistamine using PTX treated (100ng/ml) COS-7 cells co-transfected with 5 $\mu\text{g}/10^6$ cells of both pcDEF₃rH_{3AR}-G α_{01} C³⁵¹I and a CREB-responsive firefly-luciferase reporter gene (pTLNC121CRE). *B*, Evaluation of the effects of co-transfection of 0.25 $\mu\text{g}/10^6$ cells of pcDEF₃rH_{3AR}-G α_{01} C³⁵¹I together with varying amounts of pcDEF₃rH_{3D} (0 - 2.5 $\mu\text{g}/10^6$ cells) on the relative number of expressed ¹²⁵I-IPP binding sites. *C*, Effects of the co-transfection of 0.25 $\mu\text{g}/10^6$ cells pcDEF₃rH_{3AR} and 2.5 $\mu\text{g}/10^6$ cells pcDEF₃rH_{3D} on [³⁵S]GTP γ S binding to the PTX-insensitive mutant G α_{01} C³⁵¹I protein fused to the C-terminal domain of the rH_{3AR} (rH_{3AR}-G α_{01} C³⁵¹I fusion protein). Shown are the effects of co-transfection of pcDEF₃rH_{3D} on the H_{3R} agonist immpip (1 μM)-induced [³⁵S]GTP γ S binding to the rH_{3AR}-G α_{01} C³⁵¹I fusion protein in

MOL # 19299

PTX-treated cells (100 ng/ml), and the effects of the inverse H₃R agonist thioperamide (1 μM) on the 1 μM immpip-induced [³⁵S]GTPγS binding. Shown are the averages of three independent experiments.

Figure 7. Detection of oligomerisation of heterologous and native rH_{3A}Rs. *A*, Biochemical evidence for rH_{3A}R oligomers. Membranes derived from either cells heterologously expressing rH_{3A}Rs or from native rat forebrain membranes were analysed by immunoblotting (*lanes 1-3* and *4*, respectively) as described in the materials and methods section. In addition, samples of membranes expressing rH_{3A}Rs were subjected to chemical crosslinking with either 0.12mM or 0.25mM BS3 (*lanes 2* and *3*, respectively) prior to immunoblotting. Lanes 1-3 were subsequently probed with rabbit anti-H_{3C} 268-277Cys antibody (0.2 μg/ml), and lane 4 was probed with rabbit anti-H₃ 349-358 antibody (1.5 μg/ml). The immunoblot is representative of at least three separate experiments. The molecular weight (M_r) standards are displayed on the left and are indicated in kDa. *B*, Detection of dimeric rH_{3A}Rs by *time-resolved* FRET (*tr*-FRET). Upon measuring fluorescence emission at 665 nm, after excitation at 337 nm, *tr*-FRET signals are seen using live cells expressing HA-rH_{3A}Rs, due to the resonance energy transfer of specific HA-rH_{3A}Rs bound to anti-HA-Eu³⁺ antibody to the specific HA-rH_{3A}Rs bound to anti-HA-allophycocyanin antibody. *tr*-FRET signals were seen only using membranes of HA-rH_{3A}R expressing cells that were co-incubated with both the anti-HA-Eu³⁺ (Eu³⁺) antibody and the anti-HA-allophycocyanin (XL665) antibody (Eu³⁺ + XL665). Mixing of two populations of cells expressing HA-rH_{3A}Rs independently incubated with either anti-HA-Eu³⁺ or anti-HA-allophycocyanin antibodies resulted in a reduced *tr*-FRET signal. Data are plotted as as the *tr*-FRET that is observed using HA-rH_{3A}R expressing cells that have been incubated with both anti-HA-Eu³⁺ and anti-HA-

MOL # 19299

allophycocyanin antibodies *versus* the *tr*-FRET that is observed using a mix of two populations of HA-rH_{3A}R expressing cells that prior to mixing were independently incubated with either of the two antibodies.

Figure 8. Detection of rH₃ isoform mRNA in rat brain. *A*, Diagrammatic representation of mRNA sequences recognized by probes H_{3AD} and H_{3DEF}. *B*, mRNA levels of isoforms detected with probe H_{3AD}. *C*, Images of representative sections from control and 48h post-PTZ injection animals. *D*, Expression mRNA levels of isoforms detected with probe H_{3DEF}. *E*, Images of representative sections from control and 24h post-injection. Data are presented as IOD ± SEM; levels of significance are as follows: *p < 0.05; **p < 0.01; ***p < 0.001. Abbreviations: ctx II-VIb, cortex layers II to VIb; CPu, caudate putamen; Pir, piriform cortex; CA1, CA1 region of the hippocampus; CA3, CA3 region of the hippocampus.

A

```

1      10      20      30      40      50      60
rH3A  MERAPPDGLMNASGTLAGEAAAAGGARGFSAAWTAVLAALMALLIVATVTLGNALVMLAFV
rH3B  MERAPPDGLMNASGTLAGEAAAAGGARGFSAAWTAVLAALMALLIVATVTLGNALVMLAFV
rH3C  MERAPPDGLMNASGTLAGEAAAAGGARGFSAAWTAVLAALMALLIVATVTLGNALVMLAFV
rH3D  MERAPPDGLMNASGTLAGEAAAAGGARGFSAAWTAVLAALMALLIVATVTLGNALVMLAFV
rH3E  MERAPPDGLMNASGTLAGEAAAAGGARGFSAAWTAVLAALMALLIVATVTLGNALVMLAFV
rH3F  MERAPPDGLMNASGTLAGEAAAAGGARGFSAAWTAVLAALMALLIVATVTLGNALVMLAFV

61     70     80     90     100    110    120
rH3A  ADSSLRTQNNFFLLNLAISDFLVGAFCIPLVVPYVLTGRWTFGRGLCKLWLVVDYLLCAS
rH3B  ADSSLRTQNNFFLLNLAISDFLVGAFCIPLVVPYVLTGRWTFGRGLCKLWLVVDYLLCAS
rH3C  ADSSLRTQNNFFLLNLAISDFLVGAFCIPLVVPYVLTGRWTFGRGLCKLWLVVDYLLCAS
rH3D  ADSSLRTQNNFFLLNLAISDFLVGAFCIPLVVPYVLTGRWTFGRGLCKLWLVVDYLLCAS
rH3E  ADSSLRTQNNFFLLNLAISDFLVGAFCIPLVVPYVLTGRWTFGRGLCKLWLVVDYLLCAS
rH3F  ADSSLRTQNNFFLLNLAISDFLVGAFCIPLVVPYVLTGRWTFGRGLCKLWLVVDYLLCAS

121    130    140    150    160    170    180
rH3A  SVFNIVLISYDRFLSVTRAVSYRAQQGDTTRAVRKMALVWVLAFLLYGPAILLSWEYLSGG
rH3B  SVFNIVLISYDRFLSVTRAVSYRAQQGDTTRAVRKMALVWVLAFLLYGPAILLSWEYLSGG
rH3C  SVFNIVLISYDRFLSVTRAVSYRAQQGDTTRAVRKMALVWVLAFLLYGPAILLSWEYLSGG
rH3D  SVFNIVLISYDRFLSVTRAVSYRAQQGDTTRAVRKMALVWVLAFLLYGPAILLSWEYLSGG
rH3E  SVFNIVLISYDRFLSVTRAVSYRAQQGDTTRAVRKMALVWVLAFLLYGPAILLSWEYLSGG
rH3F  SVFNIVLISYDRFLSVTRAVSYRAQQGDTTRAVRKMALVWVLAFLLYGPAILLSWEYLSGG

181    190    200    210    220    230    240
rH3A  SSIPEGHCYAEFFYNWYFLITASTLEFPTPPLSVTFPFLSIYLNIQRRTRLRLDGGREAG
rH3B  SSIPEGHCYAEFFYNWYFLITASTLEFPTPPLSVTFPFLSIYLNIQRRTRLRLDGGREAG
rH3C  SSIPEGHCYAEFFYNWYFLITASTLEFPTPPLSVTFPFLSIYLNIQRRTRLRLDGGREAG
rH3D  SSIPEGHCYAEFFYNWYFLITASTLEFPTPPLSVTFPFLSIYLNIQRRTRLRLDGGREAG
rH3E  SSIPEGHCYAEFFYNWYFLITASTLEFPTPPLSVTFPFLSIYLNIQRRTRLRLDGGREAG
rH3F  SSIPEGHCYAEFFYNWYFLITASTLEFPTPPLSVTFPFLSIYLNIQRRTRLRLDGGREAG

241    250    260    270    280    290    300
rH3A  PEPPDDAQSPPPAPPSCWGCWPKGHGEAMPLHRYGVGEAGPGVEAGEAALGGSGGGAA
rH3B  PEPPDDAQSPPPAPPSCWGCWPKGHGEAMPLH-----
rH3C  PEPPDDAQSPPPAPPSCWGCWPKGHGEAMPLH-----
rH3D  PEPPDDAQSPPPAPPSCWGCWPKGHGEAMPLHRYGVGEAGPGVEAGEAALGGSGGGAA
rH3E  PEPPDDAQSPPPAPPSCWGCWPKGHGEAMPLH-----
rH3F  PEPPDDAQSPPPAPPSCWGCWPKGHGEAMPLH-----

301    310    320    330    340    350    360
rH3A  ASPTSSSGSSRGTERPRSLKRGSKPSASSASLEKRMKMVSQSIQRFRLSRDKKVAKSL
rH3B  ----SSGSSRGTERPRSLKRGSKPSASSASLEKRMKMVSQSIQRFRLSRDKKVAKSL
rH3C  ----RGSKPSASSASLEKRMKMVSQSIQRFRLSRDKKVAKSL
rH3D  ASPTSSSGSSRGTERPRSLKRGSKPSASSASLEKRMKMVSQSIQRFRLSRDKKVAKSL
rH3E  ----SSGSSRGTERPRSLKRGSKPSASSASLEKRMKMVSQSIQRFRLSRDKKVAKSL
rH3F  ----RGSKPSASSASLEKRMKMVSQSIQRFRLSRDKKVAKSL

361    370    380    390    400    410    420
rH3A  AIIVSIFGLCWAPYTLMLIIRAACHGRCIPDYWYETSFWLLWANSVAVNPVLYPLCHYSFR
rH3B  AIIVSIFGLCWAPYTLMLIIRAACHGRCIPDYWYETSFWLLWANSVAVNPVLYPLCHYSFR
rH3C  AIIVSIFGLCWAPYTLMLIIRAACHGRCIPDYWYETSFWLLWANSVAVNPVLYPLCHYSFR
rH3D  AIIVSIFGLCWAPYTLMLIIRAACHGRCIPDYCVLERLGKLEASLLLPLWMFSGRWRRRKH
rH3E  AIIVSIFGLCWAPYTLMLIIRAACHGRCIPDYCVLERLGKLEASLLLPLWMFSGRWRRRKH
rH3F  AIIVSIFGLCWAPYTLMLIIRAACHGRCIPDYCVLERLGKLEASLLLPLWMFSGRWRRRKH

421    430    440    445    450    460    470    480
rH3A  RAFTKLLCPQKLVQPHGSLEQCWK
rH3B  RAFTKLLCPQKLVQPHGSLEQCWK
rH3C  RAFTKLLCPQKLVQPHGSLEQCWK
rH3D  VCELDVPWMFNQERQNCRGARGWIGRCGLPRPPPSVLQLPAPRQQLLPAPPPGLGRWPC
rH3E  VCELDVPWMFNQERQNCRGARGWIGRCGLPRPPPSVLQLPAPRQQLLPAPPPGLGRWPC
rH3F  VCELDVPWMFNQERQNCRGARGWIGRCGLPRPPPSVLQLPAPRQQLLPAPPPGLGRWPC

481    490    497
rH3A  PACPVCTIRIWGWVVMG
rH3B  PACPVCTIRIWGWVVMG
rH3E  PACPVCTIRIWGWVVMG
rH3F  PACPVCTIRIWGWVVMG
    
```

B

```

169,155,730bp
Chromosome 3  CCCGATTACTGGTACGAGACG // TGCTGGAAGTGAGCAGCT // CCCACAAAGTGTGAGCGC // GTTATGGGGTAGAGCGC

aa in rH3A-C  P D Y W Y E T // C W K x
aa in rH3D-F  P D Y C                                     V E R // V M G x

169,155,750bp
169,155,890bp
1691,55,906bp
169,156,473bp
169,156,490bp
169,156,786bp
169,156,802bp
    
```

Figure 1




Figure 2





Figure 3

A



B




Figure 4




Figure 5





Figure 6

A



B




Figure 7




Figure 8